Sotera Health (NASDAQ:SHC) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Key Points

• Sotera Health beat quarterly estimates: EPS came in at $0.26 versus the $0.24 consensus, while revenue rose 9.2% year over year to $321.4 million, ahead of expectations.
• Full-year 2026 guidance was raised: Management now expects adjusted EPS of $0.95–$1.01, constant-currency revenue growth of 5.25%–6.75%, and adjusted EBITDA growth of 5.75%–7.25%.
• Risks remain despite strong results: The company carries roughly $2.2 billion in debt and faces litigation, regulatory and inflationary pressures; analyst sentiment is generally positive, with a $21.50 consensus price target.

Sotera Health (NASDAQ:SHC - Get Free Report) released its earnings results on Thursday. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.02, FiscalAI reports. The business had revenue of $321.38 million during the quarter, compared to analysts' expectations of $309.70 million. Sotera Health had a net margin of 13.44% and a return on equity of 40.12%. The firm's revenue was up 9.2% on a year-over-year basis. During the same period last year, the business earned $0.20 earnings per share. Sotera Health updated its FY 2026 guidance to 0.950-1.010 EPS.

Here are the key takeaways from Sotera Health's conference call:

• Strong second-quarter performance: Revenue rose 8% on a constant-currency basis, adjusted EBITDA increased 8.7%, margins expanded 36 basis points, and adjusted EPS grew 30% to $0.26.
• Sotera Health raised its 2026 outlook, now expecting constant-currency revenue growth of 5.25%-6.75%, adjusted EBITDA growth of 5.75%-7.25%, and adjusted EPS of $0.95-$1.01.
• Sterigenics delivered 7% constant-currency revenue growth, supported by pricing, volume and mix, while Nordion grew 16.7%; Sterigenics also expects second-half growth from favorable shutdown timing, a large customer outsourcing EO sterilization, and the new X-ray facility.
• Net leverage improved to 3.0 times, reaching the company’s long-term target range, while 2026 capital expenditures are expected at $200 million-$225 million for capacity expansions and facility upgrades; management expects a meaningful CapEx reduction in 2027.
• Nelson Labs’ revenue grew 5.4% in constant currency, but segment income margin declined year over year because of higher costs; management continues to forecast a full-year margin in the low-to-mid 30% range.

Sotera Health Stock Performance

Shares of NASDAQ SHC traded down $0.05 during mid-day trading on Friday, reaching $18.86. 3,375,782 shares of the company were exchanged, compared to its average volume of 3,027,352. The company's 50-day simple moving average is $17.13 and its 200-day simple moving average is $16.33. The company has a quick ratio of 2.54, a current ratio of 2.80 and a debt-to-equity ratio of 3.19. The stock has a market capitalization of $5.38 billion, a P/E ratio of 33.09 and a beta of 1.77. Sotera Health has a twelve month low of $12.94 and a twelve month high of $19.85.

Sotera Health News Summary

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SHC. JPMorgan Chase & Co. lifted their price objective on shares of Sotera Health from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Friday. Piper Sandler reiterated an "overweight" rating and set a $25.00 price target (up from $22.00) on shares of Sotera Health in a report on Friday. UBS Group set a $19.00 price target on Sotera Health in a research report on Wednesday, June 24th. The Goldman Sachs Group assumed coverage on Sotera Health in a research note on Friday, June 5th. They issued a "buy" rating and a $20.00 price objective on the stock. Finally, Weiss Ratings raised Sotera Health from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, July 9th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Sotera Health currently has a consensus rating of "Moderate Buy" and an average price target of $21.50.

Insider Buying and Selling

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the company's stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total value of $193,194,516.17. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 15.36% of the company's stock.

Institutional Investors Weigh In On Sotera Health

A number of institutional investors have recently made changes to their positions in SHC. ION Fund Management Ltd bought a new stake in shares of Sotera Health in the fourth quarter valued at about $176,000. Amundi bought a new position in Sotera Health during the fourth quarter worth about $179,000. Maryland State Retirement & Pension System acquired a new stake in Sotera Health in the 4th quarter worth about $176,000. Integrated Wealth Concepts LLC acquired a new stake in Sotera Health in the 4th quarter worth about $192,000. Finally, Focus Partners Advisor Solutions LLC bought a new stake in Sotera Health in the 4th quarter valued at about $194,000. Institutional investors own 91.03% of the company's stock.

Sotera Health Company Profile

Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source